Mr. Don Cilla reports

APPILI THERAPEUTICS ANNOUNCES RECEIPT OF FINAL COURT ORDER FOR ARRANGEMENT WITH ADITXT, INC.

Appili Therapeutics Inc. has received the final order of the Ontario Superior Court of Justice (Commercial List) for the plan of arrangement, pursuant to which Aditxt Inc., through its wholly owned subsidiary, Adivir Inc., will acquire all of the issued and outstanding Class A common shares of the company. As previously announced, the transaction was overwhelmingly approved by the company's shareholders at a special meeting held on Nov. 6, 2024.

"The successful shareholder vote and court approval represent critical milestones for Appili, bringing the transaction with Aditxt one step closer to completion," said Don Cilla, president and chief executive officer of Appili. "Through Aditxt's social innovation platform, we look forward to activating promising opportunities to improve and protect public health across the infectious disease and medical countermeasures landscape."

Closing of the transaction remains subject to the satisfaction of certain closing conditions. Subject to the satisfaction of all requisite closing conditions, the transaction is expected to close in Q4 2024.

Following completion of the transaction, the company's shares will be delisted from the Toronto Stock Exchange and the company will apply to cease to be a reporting issuer in each of the applicable jurisdictions in Canada.

For more information on the transaction, please refer to the company's management information circular dated Oct. 4, 2024, and the appended arrangement agreement, which are available on the company's SEDAR+ profile.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including an FDA-approved (U.S. Food and Drug Administration) ready-made suspension of metronidazole for the treatment of anti-microbial infections, a vaccine candidate to eliminate a serious biological weapon threat and a topical anti-parasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.